Abbott Laboratories $ABT Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp lowered its stake in shares of Abbott Laboratories (NYSE:ABT) by 0.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,678,513 shares of the healthcare product maker’s stock after selling 60,159 shares during the period. Bank of New York Mellon Corp owned 0.73% of Abbott Laboratories worth $1,698,160,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its position in shares of Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares during the period. Sivia Capital Partners LLC boosted its position in shares of Abbott Laboratories by 3.5% in the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after acquiring an additional 162 shares during the last quarter. Janney Montgomery Scott LLC grew its holdings in Abbott Laboratories by 12.4% in the second quarter. Janney Montgomery Scott LLC now owns 669,868 shares of the healthcare product maker’s stock valued at $91,109,000 after purchasing an additional 73,780 shares during the period. Spartan Planning & Wealth Management raised its stake in Abbott Laboratories by 5.5% during the second quarter. Spartan Planning & Wealth Management now owns 3,360 shares of the healthcare product maker’s stock worth $457,000 after purchasing an additional 176 shares during the period. Finally, Capital Investment Advisors LLC boosted its holdings in shares of Abbott Laboratories by 2.7% in the 2nd quarter. Capital Investment Advisors LLC now owns 23,340 shares of the healthcare product maker’s stock valued at $3,174,000 after purchasing an additional 603 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Evercore ISI cut their target price on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. The Goldman Sachs Group reduced their price objective on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Piper Sandler dropped their target price on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a research report on Friday, January 23rd. William Blair raised shares of Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, November 20th. Finally, Sanford C. Bernstein dropped their price objective on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $140.79.

Abbott Laboratories Price Performance

Shares of ABT stock opened at $108.22 on Wednesday. Abbott Laboratories has a twelve month low of $105.78 and a twelve month high of $141.23. The company has a market capitalization of $188.18 billion, a PE ratio of 29.09, a price-to-earnings-growth ratio of 1.73 and a beta of 0.72. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. The firm has a fifty day simple moving average of $123.90 and a 200-day simple moving average of $127.95.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The business had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. During the same quarter in the previous year, the firm posted $1.34 earnings per share. The company’s revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be paid a dividend of $0.63 per share. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date is Thursday, January 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories’s payout ratio is currently 67.74%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.